TY  - JOUR
AU  - Afonso, Marta B
AU  - Rodrigues, Pedro M
AU  - Mateus-Pinheiro, Miguel
AU  - Simão, André L
AU  - Gaspar, Maria M
AU  - Majdi, Amine
AU  - Arretxe, Enara
AU  - Alonso, Cristina
AU  - Santos-Laso, Alvaro
AU  - Jimenez-Agüero, Raul
AU  - Eizaguirre, Emma
AU  - Bujanda, Luis
AU  - Pareja, Maria Jesus
AU  - Banales, Jesus M
AU  - Ratziu, Vlad
AU  - Gautheron, Jeremie
AU  - Castro, Rui E
AU  - Rodrigues, Cecília M P
PY  - 2020
DO  - 10.1136/gutjnl-2020-321767
UR  - https://hdl.handle.net/10668/27147
T2  - Gut
AB  - Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3...
LA  - en
KW  - cell death
KW  - chronic liver disease
KW  - lipid metabolism
KW  - molecular carcinogenesis
KW  - nonalcoholic steatohepatitis
KW  - Animals
KW  - Biomarkers
KW  - Carcinogenesis
KW  - Cell Transformation, Neoplastic
KW  - Disease Progression
KW  - Humans
KW  - Lipid Metabolism
KW  - Liver Cirrhosis
KW  - Liver Neoplasms
KW  - Mice
KW  - Non-alcoholic Fatty Liver Disease
KW  - Prospective Studies
KW  - Receptor-Interacting Protein Serine-Threonine Kinases
TI  - RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
TY  - research article
VL  - 70
ER  -